Click here for slides on this topic


Statins

Agents used to lower serum cholesterol as a means of reducing the risk for cardiovascular disease (CVD). Also known as statins. Also called HMG-CoA reductase inhibitors.
The following content matched the glossary term: Statins

AHA ADA prevention of CVD in T2D - Cholesterol Management

Top

Summary of cholesterol management recommendations from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study

Top

Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014. [ePub ahead of print] doi: 10.1016/S2213-8587(14)70173-1.

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

Top

Dormuth CR, Filion KB, Paterson JM, et al; for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244.

Statins and the risk of diabetes: evidence from a large population-based cohort study

Top

Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225-2232.

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

ADA 2016 Cardiovascular Disease (CVD) and Diabetes

Top

Recommendations for CVD management, including lipids and BP, in patients with type 2 diabetes from the 2016 ADA diabetes guidelines

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

1 2 3 4 5 Next 

Slide Library Results

Search Results for: Statins Slides Found: 84
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Diabetes Is Undertreated Even When Atherosclerosis Present
Results From Statin Trials for Patients With Diabetes
SPARCL: Primary Outcome of Fatal or Nonfatal Stroke
SPARCL: First Events
Drug Nonadherence Is Associated With Adverse Clinical Outcomes in Diabetes
ADOPT: Adverse Events
Proportion of Diabetic Patients With Low HDL-C Stratified by Treatment, Sex, and Cardiovascular Disease
ADVANCE: Study Design
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
Statin Use and Risk for Diabetes: Design
Statin Use and Risk for Diabetes: Results
JUPITER: Design
JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?
JUPITER Analysis: Design
JUPITER Analysis: Baseline Characteristics 0 or ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Increased Diabetes Risk With ≥1 Risk Factor* at Baseline
JUPITER Analysis: Incident Diabetes by Treatment Group
JUPITER Analysis: Average Time to Diabetes Diagnosis
JUPITER Analysis: Risk Reduction With Rosuvastatin ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Risk Reduction With Rosuvastatin No Major Diabetes Risk Factor*
JUPITER Analysis: CV Risk Reduction Among Subjects Who Developed Diabetes
JUPITER Analysis: Conclusions
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
JUPITER: Study Design
JUPITER: Lipid and HsCRP Levels
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
JUPITER Results: Summary
JUPITER Analysis: Limitations
FIN-D2D: Association Between Statin Use and Diabetes Incidence Design
FIN-D2D: Statin Use at Baseline and Diabetes Incidence At 1 Year
FIN-D2D: Statin Use at Baseline and Glucose Values at 1 Year
VADT Post-hoc Analysis: Satin Use and CAC Progression
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
HPS2-THRIVE: Niacin and Vascular Risk
AIM-HIGH: Baseline Characteristics
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
Meta-Analysis: New-Onset Diabetes and CV Events With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: New-Onset Diabetes With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: CV Events With Intensive- Vs Moderate-Dose Statins
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin Over 14 Years
Incident Diabetes Rate Greater with High- Vs Moderate- or Low-Potency Statins
Tolerability and Harms of Statin Therapy: Meta-Analysis
Statins and Diabetes, Cancer: Meta-Analysis
Intensive Statin Therapy and Adverse Events: Meta-Analysis
Mortality & Cardiovascular Benefits of Statins: Meta-Analysis
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin for Primary and Secondary Prevention
Incident Diabetes by Statin Use: Design
ACC/AHA Cholesterol Guidelines 2013: High- and Moderate-Intensity Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
IDF Type 2 Diabetes Guidelines CVD Risk Reduction Treatment | NDEI
Diabetes Pregnancy Guidelines Preconception CVD Dyslipidemia | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Statin Adherence Associated With Increased Type 2 Diabetes Risk | NDEI
Statin Adherence & Type 2 Diabetes Risk | NDEI
Statin Adherence & Risk for New-Onset Type 2 Diabetes | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
Metformin Sulfonylureas Cancer Risk Type 2 Diabetes | NDEI
Statin Use and the Risk of Microvascular Disease | NDEI
Statin Use Not Associated With an Increased Microvascular Risk Slide | NDEI
Pregnancy Recommendations ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Hyperglycemia Management in Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
Combination Statin Therapy in Type 2 Diabetes ADA Guidelines | NDEI PPT
Statins & Diabetes Risk ADA Guidelines 2016 | NDEI PPT
ADA Guidelines for Treating Dyslipidemia in Children With Type 1 Diabetes | NDEI
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Rosuvastatin & Incident Type 2 Diabetes | NDEI
JUPITER Insulin Resistance Associated With Risk Factors | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI
GAUSS-3 Evolocumab Reduces LDL-C in Statin-Intolerant Patients | NDEI
GAUSS-3 Absolute LDL-C Reduction With Evolocumab Statin Intolerance | NDEI
GAUSS-3: LDL-C Goal Achievement With Evolocumab Statin Intolerance | NDEI
GAUSS-3 Evolocumab Effects on Lipoproteins in Statin-Intolerant Patients | NDEI
GAUSS-3 Evolocumab Use in Statin-Intolerant Patients Muscle Symptoms | NDEI
GAUSS-3 Muscle-Related Adverse Events With Evolocumab & Ezetimibe | NDEI
GAUSS-3 Design Evolocumab Vs Ezetimibe in Statin Intolerance | NDEI